Welcome to our dedicated page for ONTX news (Ticker: ONTX), a resource for investors and traders seeking the latest updates and insights on ONTX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ONTX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ONTX's position in the market.
Onconova Therapeutics (NASDAQ: ONTX) has successfully closed an underwritten public offering, selling 5,000,000 shares of common stock at $4.20 each, raising gross proceeds of $21 million. The underwriters have an option to purchase an additional 750,000 shares. The offering was made under a shelf registration statement initially filed with the SEC in April 2020. Guggenheim Securities acted as the sole book-running manager, supported by Ladenburg Thalmann & Co. Inc. and Noble Capital Markets, Inc. The funds are expected to support Onconova’s ongoing clinical trials and development of novel cancer therapies.
Onconova Therapeutics (NASDAQ: ONTX) announced a public offering of 5,000,000 shares at $4.20 each, expected to generate $21 million in gross proceeds. An additional 750,000 shares can be purchased by underwriters within 30 days. The closing is anticipated around September 28, 2021, subject to standard conditions. The offering is conducted under a shelf registration statement effective since May 2020. Guggenheim Securities acts as the sole book-running manager, with Ladenburg Thalmann and Noble Capital Markets as co-managers.
Onconova Therapeutics, Inc. (NASDAQ: ONTX) announced plans for a public offering of its common stock, with shares being offered solely by the company. The offering's size and terms remain uncertain and are subject to market conditions. Guggenheim Securities serves as the sole book-running manager. Proceeds will support working capital and corporate uses, with interim investments in short-term, interest-bearing securities. The offering will be made under a previously filed shelf registration statement.
Onconova Therapeutics recently shared preliminary data from a Phase 1/2a trial involving rigosertib combined with nivolumab for patients with advanced KRAS mutated non-small cell lung cancer (NSCLC). Results indicated a 29% partial response rate among evaluable patients, with responses observed across different KRAS mutations (G12C, G12V). The combination therapy was well tolerated, showing potential to overcome resistance to prior treatments. A webinar discussing results took place on September 22, 2021.
Onconova Therapeutics (NASDAQ: ONTX) announced a presentation scheduled for September 22, 2021, at the Annual RAS Targeted Drug Development Summit. The presentation will showcase data from a Phase 1/2a investigator-initiated study exploring the combination of rigosertib and nivolumab in patients with KRAS mutated non-small cell lung cancer (NSCLC). Dr. Rajwanth Veluswamy from the Icahn School of Medicine will lead the presentation titled 'Phase 1 Clinical Trial Updates for Oral Rigosertib & PD-1 Inhibitor in KRAS-mutated NSCLC,' highlighting important findings in cancer treatment.
Onconova Therapeutics, Inc. (NASDAQ: ONTX) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13-15, 2021. A corporate overview will be presented by CEO Steven Fruchtman, available from September 13 at 7:00 a.m. ET. Onconova is engaged in clinical-stage development of cancer therapies, including ON 123300 and rigosertib, both undergoing significant studies in the U.S. and China. Forward-looking statements highlight potential risks and uncertainties related to clinical trials and regulatory processes.
Onconova Therapeutics, Inc. (NASDAQ: ONTX) announced its second quarter 2021 financial results and business updates, highlighting the completion of enrollment in the first cohort of the ON 123300 Phase 1 solid tumor study in the U.S. and ongoing studies in China with no observed dose limiting toxicities. The company reported a net loss of $4.2 million, down from $7.4 million year-over-year, with cash and equivalents of $43.7 million, expected to fund operations for over 18 months. Upcoming milestones include progress in clinical trials and potential asset acquisitions.
Onconova Therapeutics (NASDAQ: ONTX) will release its second quarter 2021 financial results on August 12, 2021. A conference call and webcast will be held at 4:30 p.m. ET to discuss the results and pipeline updates. The company is focused on developing novel cancer therapies, including the multi-kinase inhibitor ON 123300 and rigosertib for specific lung cancer treatments. Onconova's advancements are crucial as they continue to navigate clinical trials and regulatory processes.
Onconova Therapeutics, Inc. (NASDAQ: ONTX) provided an update on its Phase 1/2a trial of oral rigosertib and nivolumab for advanced metastatic KRAS+ non-small cell lung cancer (NSCLC). Preliminary data show potential anti-cancer activity, with the maximum tolerated dose yet to be reached. The trial is expanding patient recruitment at the highest dose, and a protocol amendment will evaluate increased rigosertib doses. Encouraging preliminary results indicate efficacy and acceptable safety. The trial supports preclinical observations linking rigosertib to enhanced immune responses.
On June 17, 2021, Onconova Therapeutics (NASDAQ: ONTX) announced it has regained compliance with Nasdaq's minimum bid price rule, achieving a closing bid price of at least $1.00 for 18 consecutive business days. This compliance is crucial for maintaining its listing on the exchange. The company is actively developing targeted anti-cancer therapies, including ON 123300, which is currently in Phase 1 trials in the U.S. and China, and rigosertib, which is in a Phase 1/2a study for KRAS+ non-small cell lung cancer.